Radiation therapy after chemo for limited biliary tract cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding targeted radiation therapy (called consolidative radiotherapy) after standard chemotherapy can help control biliary tract cancer that has spread to a few places. It is for people whose cancer has not grown during initial chemotherapy and who have a limited number of treatable spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biliary tract cancer that has spread to a few spots (up to 5 total, no more than 3 in one organ like the liver or lung).
- You have already received 4 cycles of first-line chemotherapy, and your latest scan shows the cancer has not grown.
- All of the cancer spots can be safely treated with targeted radiation therapy.
- You are 18 years or older, and your general health is good enough to take care of yourself (ECOG score 0-1).
- Your blood counts and liver/kidney function are within safe limits for radiation treatment.
- You have not had any prior radiation or surgery to these specific cancer spots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) for biliary tract cancer that can be removed by surgery. The goal is to prevent cancer from coming back after surgery.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
This trial tests a combination of radiation therapy (SBRT), two chemotherapy drugs (gemcitabine and cisplatin), and an immunotherapy drug (sintilimab) as a first-line treatment for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding targeted radiation (radiotherapy) to standard second-line chemotherapy helps people with advanced intrahepatic bile duct cancer that has spread to a limited number of spots (oligometastatic). It is for those whose first treatment stopped working.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.